Utilizing non-clonal CHO cell derived materials for preclinical studies of complex molecules

Area of Science:

• Biotechnology
• Cell Line Development
• Biopharmaceutical Manufacturing

Background:

• Non-clonal Chinese hamster ovary (CHO) cell derived materials offer a promising strategy to expedite the development of monoclonal antibodies (mAbs) for initial clinical trials.
• Assessing culture performance, productivity, and product quality of non-clonal versus clonal cell lines is crucial for complex biologics.

Purpose of the Study:

• To evaluate the feasibility of using non-clonal CHO cell derived materials for preclinical and clinical studies of complex biologic molecules.
• To compare the performance and quality attributes of biologics produced from stable pools, pools of top clones, and lead clones.

Main Methods:

• Transposase-mediated integration was used to generate stable pools, pools of top clones, and lead clones.
• Evaluated culture performance, productivity, and product quality for a multi-specific antibody, a cytokine-Fc fusion protein, and a mAb.
• Conducted preclinical and clinical manufacturing of multi-specific antibodies using both pools of top clones and lead clones.

Main Results:

• Product attributes were comparable across cell sources (stable pool, pool of top clones, lead clone).
• Preclinical and clinical manufacturing batches using pools of clones and lead clones showed high comparability.
• Non-clonal CHO cell derived materials maintained consistent culture performance, productivity, and product quality.

Conclusions:

• Non-clonal CHO cell derived materials are suitable for preclinical studies of complex molecules.
• Utilizing non-clonal materials does not compromise product quality, facilitating accelerated development for first-in-human (FIH) studies.
• This approach supports efficient biopharmaceutical development pathways.